Skip to main content
Signal8
Launch Terminal

Structure Therapeutics Inc. (GPCR)

Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Structure Therapeutics Inc. logo

Structure Therapeutics Inc.

NASDAQ:GPCRHealthcare
-0.32%$21.87
AH$22.01+0.64%vs close
Mkt Cap$1.56B
Float28.65M
O/S71.31M
Vol
$ Vol
RVOL
Inst Own94.7%
SI24.9%
Earnings
Dilution
Structure Therapeutics Inc. logoNASDAQ:GPCR$21.87-0.32%
Phase Distribution
11 lead-sponsored trials·3 active·6 completed
Phase 13
Phase 1/22
Phase 24
Phase 32
Status Overview
Not yet recruiting1
Recruiting3
Completed6
Unknown1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Recruiting

    Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

    Aleniglipron, Placebo

    Obesity, Overweight +1

    Enrollment
    3,600
    Start
    Jul 2026
    Primary Completion
    Sep 2028est.
    Completion
    Nov 2028est.
    NCT07654361
  • Phase 3
    Recruiting

    A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

    aleniglipron, aleniglipron

    Obesity, Overweight +2

    Enrollment
    1,100
    Start
    Jul 2026
    Primary Completion
    Sep 2028est.
    Completion
    Nov 2028est.
    NCT07654374
  • Phase 2
    Completed

    A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

    Aleniglipron or Placebo, Aleniglipron or Placebo

    Obesity, Overweight, or Chronic Weight Management

    Enrollment
    230
    Start
    Oct 2024
    Primary Completion
    Oct 2025
    Completion
    Jul 2026
    NCT06693843
  • Phase 2
    Completed

    A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

    aleniglipron or placebo, aleniglipron or placebo

    Obesity, Overweight +1

    Enrollment
    85
    Start
    Dec 2024
    Primary Completion
    Jan 2026
    Completion
    Jan 2026
    NCT06703021
  • Phase 2
    Completed

    Aleniglipron Phase 2 Body Composition Study

    aleniglipron or placebo

    Obesity, Overweight, or Chronic Weight Management

    Enrollment
    71
    Start
    Aug 2025
    Primary Completion
    Sep 2026
    Completion
    Sep 2026
    NCT07169942
  • Phase 2
    Completed

    Aleniglipron Phase 2 in Type 2 Diabetes Mellitus

    Aleniglipron, Placebo

    Obese, Obesity +2

    Enrollment
    58
    Start
    Dec 2025
    Primary Completion
    Sep 2026
    Completion
    Sep 2026
    NCT07400588
  • Phase 1/2
    Completed

    Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

    GSBR-1290, Placebo

    Overweight or Obesity, Type2 Diabetes Mellitus

    Enrollment
    142
    Start
    Jan 2023
    Primary Completion
    Apr 2024
    Completion
    Apr 2024
    NCT05762471
  • Phase 1/2
    Recruiting

    First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671

    ACCG-2671, Placebo

    Obesity

    Enrollment
    164
    Start
    Dec 2025
    Primary Completion
    Mar 2027est.
    Completion
    Apr 2027est.
    NCT07815678
  • Phase 1
    Completed

    A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants

    GSBR-1290

    Healthy Volunteers

    Enrollment
    18
    Start
    Apr 2023
    Primary Completion
    Jun 2023
    Completion
    Jun 2023
    NCT05893043
  • Phase 1
    Unknown status

    A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants

    GSBR-1290 (Capsule/Tablet), GSBR-1290

    Healthy Volunteers

    Enrollment
    70
    Start
    Oct 2023
    Primary Completion
    Mar 2024est.
    Completion
    Mar 2024est.
    NCT06139055
  • Phase 1
    Not yet recruiting

    Aleniglipron Hepatic Impairment Study

    Aleniglipron

    Hepatic Impairment

    Enrollment
    36
    Start
    Oct 2026est.
    Primary Completion
    Aug 2027est.
    Completion
    Dec 2027est.
    NCT07872033
Search ClinicalTrials.gov for “Structure Therapeutics”